Abstract Details

Title Slowing of Rapid Number Naming by King-Devick Test in Parkinson's Disease

Topic Movement Disorders

Presentation(s) P04 - (-)

Poster/Presentation
Number 173

Objective

Background BACKGROUND: The King-Devick (K-D) test measures the speed of rapid number naming, and is postulated to be sensitive in capturing impairment of eye movements, attention, language, and possibly other aspects of cognitive function. While used in multiple sports concussion studies, it has not been applied to the field of movement disorders.

Design/Methods DESIGN/METHODS: A total of 25 PD and 71 controls were enrolled in the study. All were participants in the Arizona PD Consortium/Banner Sun Health Research Institute Brain and Body Donation Program. Participants read aloud a series of single-digit numbers from left to right on 3 different test cards in two consecutive trials. The sum time of all 3 cards from the faster trial was designated the final test score. The mean K-D scores from the PD and control groups were compared by the two-sample t-test. Adjusted means were compared by using a general linear model with terms for PD, age, and sex.

Results RESULTS: The mean age was younger in PD (73.8 ± 7.4 years) vs. controls (80.9 ± 6.2 years). More men were in the PD group (68% PD vs. 34% Control). The mean PD duration was 9.3 + 5.9 years (range 1.5-25 years). The mean K-D score for the PD group (60.9 ± 19.8 seconds) was statistically higher compared to the control group (50.4 ± 9.8 seconds), p = 0.001. After adjusting for age and sex, the mean K-D score remained higher in the PD group (63.7 seconds) vs. controls (49.0 seconds), p < 0.001.

Conclusions CONCLUSIONS: This is the first study of the King-Devick Test in Parkinson's disease. PD patients were found to have a slower rapid number naming speed compared to controls. Therefore, the King-Devick test may be a rapid tool for quantifying visual and cognitive function in Parkinson's disease.

Authors/Disclosures
Tanya Lin, MD PRESENTER	Dr. Lin has nothing to disclose.
Charles H. Adler, MD, PhD, FAAN (Mayo Clinic Arizona)	Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avion. Dr. Adler has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for CND Life Sci. Dr. Adler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jazz. Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Precon. Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. The institution of Dr. Adler has received research support from NIH. The institution of Dr. Adler has received research support from Michael J. Fox Foundation. The institution of Dr. Adler has received research support from Arizona Biomedical Research Commission. Dr. Adler has received publishing royalties from a publication relating to health care.
	No disclosure on file
Joseph Hentz (Mayo Clinic)	No disclosure on file
Laura J. Balcer, MD, MSCE, FAAN (NYU Grossman School of Medicine)	An immediate family member of Dr. Balcer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Children's Hospital of Philadelphia.
Steven Galetta, MD, FAAN (NYU Langone Medical Center)	Dr. Galetta has nothing to disclose.
	No disclosure on file
Nils Henninger, MD, PhD, FANA, FWSO (UMass Memorial Medical Center)	Dr. Henninger has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Henninger has stock in United Health. Dr. Henninger has stock in Novo Nordisk. Dr. Henninger has stock in Elli Lilly. Dr. Henninger has stock in Kenvue. Dr. Henninger has stock in Voyager. Dr. Henninger has stock in Alnylam. Dr. Henninger has stock in Entrada. The institution of Dr. Henninger has received research support from NIH. Dr. Henninger has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Verge Genomics.
	No disclosure on file

��ɫ��

��ɫ��